Common Clinical Cardiology Scenarios

Hanna Al-Makhamreh, MD FACC

Professor Of Cardiology

Case 1

- **History**:
- A 65-year-old gentleman presents to the ED with crushing retrosternal chest pain of 2 hours duration.
- PMH:DM, HTN and dyslipidemia.
- Meds: Insulin, metformin, enalapril, atorvastatin.
- **Exam**: Apprehension, diaphoretic and in severe pain (impending doom)
- V/S: BP 90/50mmHG, HR 110/min
- CV: Normal S1, S2 no murmur

What is the NEXT STEP ?

ECG



Normal ECG



Diagnosis: STEMI

- Transmural myocardial ischemia and subsequent myocardial injury or necrosis.
- Life threatening condition with high mortality
- Risk factors include: hypertension, hyperlipidemia, smoking, and diabetes
- The pathogenic mechanism typically involves plaque rupture and thrombus formation within the coronary artery
- Diagnosis :ECG and confirmed by elevation in cardiac biomarker Troponin

Management

- Immediate treatment involves restoring blood flow to the affected area through reperfusion therapy
- Typically, via percutaneous coronary intervention. Early management is critical to limit myocardial damage, and adjunctive therapies, including antiplatelets and anticoagulants.
- Alternative therapy is thrombolytics

PCI



Case-2

- **History:**
- A 20-year-old college student who is previously healthy present with sudden onset sharp retrosternal chest pain that is exacerbated by inspiration and laying in supine position but improves with leaning forward.
- Recent history of respiratory tract infection two weeks ago.
- **Exam:**

V/S :BP 120/80mmHg, HR 90/min

CV: squeaking sound best heard in the left parasternal area (friction rub)

What is the NEXT STEP ?

ECG



Pericarditis

- **I-Chest pain:**
- The vast majority of patients with acute pericarditis present with chest pain (>95% of cases).
- Chest pain that results from acute pericarditis is typically fairly sudden in onset and occurs over the anterior chest.
- Chest pain due to pericarditis is most often sharp and pleuritic in nature, ***with exacerbation by inspiration or coughing.***
- One of the most distinct features is the **tendency for a decrease in intensity when the patient sits up and leans forward.**

Pericardium

- **Introduction:**
- The pericardium is a fibroelastic sac made up of visceral and parietal layers separated by a space, the pericardial cavity.
- In healthy individuals, the pericardial cavity contains 15-50 mL of an ultrafiltrate of plasma.

Pericardium



Pericardium



Pericarditis

- Chest pain — typically sharp and pleuritic, improved by sitting up and leaning forward.
- Pericardial friction rub — a superficial scratchy or squeaking sound best heard with the diaphragm of the stethoscope over the left sternal border.
- Electrocardiogram (ECG) changes — new widespread ST elevation and PR depression
- Pericardial effusion.

Treatment

- For most patients with acute idiopathic or viral pericarditis, combination therapy: colchicine plus NSAIDs rather than NSAIDs alone.
- This is based upon a reduced rate of recurrent pericarditis and a low incidence of side effects with colchicine.
- Steroids are second line; the patient has side effect or allergic to NSAIDs .No response to NSAIDs

Feared complication

Case-3

- **History:**

A 60-year-old lady with history of dyspnea, orthopnea and PND’s of 3 weeks duration.

PMH: DM, HTN, CAD-CABG

Exam:

V/S: BP100/60mm HG, HR 95/min

CV: S3 sound, raised JVP

Lungs: crackles

LE: pitting edema

What is the NEXT STEP ?

CXR (congestive heart failure) and BNP Level



Heart Failure Definition

Heart failure (HF) is a clinical syndrome in which patients have **typical symptoms and signs** resulting **from** an **abnormality of cardiac structure or function** which **impairs the ability of the ventricle to fill with or eject blood**.

- **symptoms** (e.g. breathlessness, orthopnea, paroxysmal nocturnal dyspnoea, ankle swelling, fatigue, and reduced exercise tolerance)
- **signs** (e.g. elevated jugular venous pressure, hepatojugular reflux, third heart sound [gallop rhythm], cardiac murmur, and displaced apex beat)

Signs

Figure 24. CXR Showing Acute Decompensated Heart Failure

Sub-types (Echocardiogram)



Classification of Heart Failure

Functional Classification(New York Heart Association [NYHA])

Class	Severity of symptoms and limitation of physical activity
I	**No limitation** of physical activity Ordinary physical activity does not cause symptoms of HF (breathlessness, fatigue, or palpitations)
II	**Slight limitation** of physical activity Comfortable at rest, but **ordinary physical activity results in symptoms of HF**
III	**Marked limitation** of physical activity Comfortable at rest, but **less than ordinary physical activity causes symptoms of HF***
IV	**Unable** to carry on any physical activity without discomfort/symptoms of HF, or symptoms of HF at rest may be present

Classification of Heart Failure

- **Heart Failure Staging**

Stages of HF	Development and progression of HF	Corresponding NYHA Class
A	At **high risk** for HF but **without structural heart disease or symptom**s of HF	**None**
B	**Structural** heart disease but **without signs or symptoms** of HF	**I**
C	**Structural** heart disease **with prior or current symptoms** of HF	**I**
		II
		III
D	**Refractory HF** requiring specialized interventions	**IV**

Symptoms


LEFT SIDED FAILURE
• Paroxysmal Nocturnal Dyspnea
• Elevated Pulmonary Capillary Wedge Pressure
• Pulmonary Congestion
- Cough
- Crackles
- Wheezes
- Blood-Tinged Sputum
- Tachypnea
• Restlessness
• Confusion
• Orthopnea
• Tachycardia
• Exertional Dyspnea
• Fatigue
• Cyanosis
©2007 Nursing Education Consultants, Inc.


RIGHT SIDED FAILURE
(Cor Pulmonale)
• Fatigue
• ↑ Peripheral Venous Pressure
• Ascites
• Enlarged Liver & Spleen
• May be secondary to chronic pulmonary problems
• Distended Jugular Veins
• Anorexia & Complaints of GI Distress
• Weight Gain
• Dependent Edema
©2007 Nursing Education Consultants, Inc.

HFrEF Management

Pharmacological treatments indicated in patients with HFrEF (LVEF ≤40%; NYHA class II–IV)

Recommendations	Class of recommendation	Level of evidence
An ACEi is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death	I	A
A BB is recommended for patients with stable HFrEF to reduce the risk of HF hospitalization and death	I	A
An MRA is recommended for patients with HFrEF to reduce the risk of HF hospitalization and death	I	A
Dapagliflozin / empagliflozin are recommended for patients with HFrEF to reduce the risk of HF hospitalization and death	I	A
Sacubitril/valsartan is recommended as a replacement for an ACEi in patients with HFrEF to reduce the risk of HF hospitalization and death	I	B

Thank you